Epigenetic Mechanisms in Temporal Lobe Epilepsy

Temporal lobe epilepsy (TLE) is a complex neurological disorder characterised by recurrent seizures originating in the mesial structures of the temporal lobe, notably the hippocampus. Beyond classical genetic mutations, accumulating evidence highlights that heritable modifications of chromatin and DNA—collectively termed epigenetic mechanisms—play a central role in the initiation, progression and potential remission of TLE. Key processes include DNA methylation, histone modification and non-coding RNA regulation, each of which can alter gene expression patterns without changing the underlying DNA sequence. Aberrant DNA methylation in neuronal promoters or gene bodies can silence or activate critical genes involved in synaptic plasticity, neurotransmitter balance and neuroinflammation. Dysregulated activity of enzymes such as histone deacetylases (HDACs) rewires chromatin accessibility, influencing networks of pro- and anticonvulsive proteins. Emerging work also implicates circular RNAs and microRNAs in fine-tuning the epigenetic landscape of epileptogenic circuits. Together, these mechanisms not only underpin maladaptive neuronal rewiring but also offer a new class of targets for disease-modifying therapies aimed at preventing epileptogenesis or reducing pharmacoresistance.

Research from Nature Portfolio

Recent animal studies have shown that acquired epileptogenesis is accompanied by widespread alterations in DNA methylation profiles in hippocampal subfields. Comparative analyses across distinct rat models of limbic injury revealed that while genome-wide hypermethylation is a common feature of chronic epilepsy, the precise pattern of methylation changes differs according to the underlying insult, underscoring the importance of etiology-specific epigenetic signatures. In parallel, work on human patients with mesial temporal lobe epilepsy has demonstrated that peripheral blood exhibits distinct methylation changes at both promoter and coding regions of genes linked to ion transport, oxidative metabolism and drug metabolism. These blood-based signatures correlate with duration of disease, drug resistance and neuroimaging markers of hippocampal sclerosis, suggesting potential for minimally invasive biomarkers to stratify patients and monitor epigenetic responses to therapy.

Epigenetic Mechanisms in Temporal Lobe Epilepsy publication trend

The graph below shows the total number of articles in epigenetic mechanisms in temporal lobe epilepsy across all publications each year (not limited to Nature Index journals).

Technical terms

Epigenetic: Heritable changes in gene activity or expression without alteration of the DNA sequence, often mediated by DNA methylation, histone modification or non-coding RNAs.

DNA methylation: The addition of methyl groups to cytosine bases in DNA, typically at CpG sites, affecting chromatin structure and gene transcription.

Histone deacetylase (HDAC): An enzyme that removes acetyl groups from histone proteins and other substrates, leading to chromatin condensation and transcriptional repression.

Promoter region: A DNA sequence upstream of a gene that serves as the binding site for transcriptional machinery to initiate gene expression.

Hippocampus: A seahorse-shaped structure in the temporal lobe essential for memory formation and a common focus for seizure generation in TLE.

References

1. Unveiling the role of histone deacetylases in neurological diseases: focus on epilepsy. Biomarker Research (2024).
2. Emerging Molecular Targets for Anti-Epileptogenic and Epilepsy Modifying Drugs. International Journal of Molecular Sciences (2023).
3. Etiology matters – Genomic DNA Methylation Patterns in Three Rat Models of Acquired Epilepsy. Scientific Reports (2016).
4. Blood DNA methylation pattern is altered in mesial temporal lobe epilepsy. Scientific Reports (2017).
5. Possible epigenetic regulatory effect of dysregulated circular RNAs in epilepsy. PLOS ONE (2018).
6. Unique Behavioral Characteristics and microRNA Signatures in a Drug Resistant Epilepsy Model. PLOS ONE (2014).